Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
6.20
-0.09 (-1.43%)
At close: Apr 28, 2026, 4:00 PM EDT
6.25
+0.05 (0.81%)
Pre-market: Apr 29, 2026, 8:49 AM EDT
Candel Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 454 | 310 | 369 | 43 | 52 | 224 | |
| Market Cap Growth | 93.44% | -15.87% | 767.25% | -17.80% | -76.95% | - | |
| Enterprise Value | 383 | 230 | 368 | 22 | -3 | 137 | |
| Last Close Price | 6.20 | 5.65 | 8.68 | 1.47 | 1.79 | 7.82 | |
| PS Ratio | - | - | - | - | 413.76 | 1794.84 | |
| PB Ratio | 6.56 | 5.97 | 5.56 | 3.34 | 1.08 | 3.50 | |
| P/TBV Ratio | 8.75 | 5.97 | 5.56 | 3.34 | 1.08 | 3.50 | |
| EV/Sales Ratio | - | - | - | - | - | 1092.09 | |
| Debt / Equity Ratio | 0.94 | 0.94 | 0.20 | 1.79 | 0.48 | 0.01 | |
| Net Debt / Equity Ratio | -1.36 | -1.36 | -1.34 | -0.99 | -0.99 | -1.28 | |
| Net Debt / EBITDA Ratio | 1.49 | 1.49 | 2.76 | 0.34 | 1.39 | 3.22 | |
| Net Debt / FCF Ratio | 1.82 | 1.82 | 3.30 | 0.37 | 1.44 | 3.41 | |
| Asset Turnover | - | - | - | - | 0.00 | 0.00 | |
| Quick Ratio | 13.31 | 13.31 | 2.74 | 2.50 | 12.48 | 15.41 | |
| Current Ratio | 13.49 | 13.49 | 2.77 | 2.59 | 12.81 | 15.84 | |
| Return on Equity (ROE) | -64.58% | -64.58% | -139.56% | -125.50% | -33.61% | -80.60% | |
| Return on Assets (ROA) | -25.95% | -25.95% | -28.14% | -39.95% | -26.01% | -25.22% | |
| Return on Capital Employed (ROCE) | -41.50% | -41.50% | -48.10% | -140.70% | -48.20% | -30.70% | |
| Earnings Yield | -8.41% | -12.31% | -14.97% | -89.24% | -36.34% | -16.10% | |
| FCF Yield | -8.57% | -12.54% | -7.33% | -81.63% | -63.26% | -10.72% | |
| Buyback Yield / Dilution | -67.19% | -67.19% | -9.47% | -0.39% | -52.72% | -62.49% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.